Skip to content

Advertisement

  • Poster presentation
  • Open Access

Investigating possible fraudulent activity at a research site

  • Carol Knott1,
  • Joanne Henderson1,
  • Louise Bowman1 and
  • Martin Landray1
Trials201516(Suppl 2):P193

https://doi.org/10.1186/1745-6215-16-S2-P193

Published: 16 November 2015

Keywords

Corrective ActionMonitoring CommitteeProfessional BodySystemic TrialData Monitoring Committee

Background

A risk-based approach to monitoring clinical trials aims to detect non-compliance with the protocol or regulatory requirements that may compromise the participants’ well-being or the trial’s ability to produce reliable results.

Method

We describe a pragmatic framework for investigating and evaluating suspicions of poor performance/practice and the steps to be taken if findings suggest fraudulent activity.

Prior to site audit:

  • Check reliability of information that prompted concerns

  • Prepare dossier of site information, detailing suspect data points

  • Arrange visit promptly (but without indicating concerns)

During audit:

  • Two auditors: one to ask open questions, the other as witness and scribe.

  • Interview staff individually, establishing their knowledge of trial procedures and incident. Note conflicting information.

  • Establish key facts:

  1. 1.

    Were participants real and eligible?

     
  2. 2.

    Did they consent?

     
  3. 3.

    Are test/clinical measurements/data valid?

     
  4. 4.

    Was appropriate treatment/intervention given?

     
  5. 5.

    Was follow-up provided, were events reported?

     
  6. 6.

    Are participants safe and data reliable?

     
  • Obtain documentary evidence, maintaining confidentiality of trial participants

  • Document findings

After audit:

  • Implement corrective actions to:

  1. 1.

    Ensure safety of participants

     
  2. 2.

    Address important deficiencies in data quality

     
  3. 3.

    Support site: training, additional monitoring/support, replace staff.

     
  • Look for systemic trial quality issues e.g. other staff, other data

  1. 1.

    Apply lessons/corrective actions to the whole trial

     
  • Notify appropriate parties: Sponsor, steering committee, data monitoring committee, regulatory body, ethics board, host institution, funder, and professional bodies.

Conclusion

Cases of serious misconduct or fraud do occur. Taking a systematic approach to an investigation ensures appropriate action is taken to preserve study intergrity.

Authors’ Affiliations

(1)
Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

Copyright

© Knott et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement